HLB Life Science Co. Ltd (067630) — Cash Flow-to-Debt Ratio
HLB Life Science Co. Ltd (067630) has a Cash Flow-to-Debt Ratio of -0.02x as of September 2025, meaning its operating cash flow of ₩-4.30 Billion could theoretically repay 0% of its total liabilities (₩173.00 Billion) in one year. See HLB Life Science Co. Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
HLB Life Science Co. Ltd Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for HLB Life Science Co. Ltd across 13 annual periods. Also explore HLB Life Science Co. Ltd (067630) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for HLB Life Science Co. Ltd (2012–2024)
Year-by-year debt coverage analysis for HLB Life Science Co. Ltd. For market capitalisation and broader financial context, see market cap of HLB Life Science Co. Ltd.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.23x | ₩-32.01 Billion | ₩140.19 Billion | ▼ -338.3% |
| 2023 | -0.05x | ₩-10.02 Billion | ₩192.29 Billion | ▲ +69.0% |
| 2022 | -0.17x | ₩-29.74 Billion | ₩177.07 Billion | ▲ +70.6% |
| 2021 | -0.57x | ₩-14.08 Billion | ₩24.61 Billion | ▼ -1239.3% |
| 2020 | 0.05x | ₩2.01 Billion | ₩40.02 Billion | ▲ +128.8% |
| 2019 | -0.17x | ₩-12.39 Billion | ₩71.11 Billion | ▼ -163.0% |
| 2018 | -0.07x | ₩-11.07 Billion | ₩167.17 Billion | ▼ -913.0% |
| 2017 | -0.01x | ₩-302.04 Million | ₩46.19 Billion | ▲ +84.2% |
| 2016 | -0.04x | ₩-2.27 Billion | ₩54.99 Billion | ▲ +84.0% |
| 2015 | -0.26x | ₩-4.34 Billion | ₩16.80 Billion | ▼ -149.4% |
| 2014 | 0.52x | ₩10.43 Billion | ₩19.95 Billion | ▲ +559.4% |
| 2013 | 0.08x | ₩2.95 Billion | ₩37.19 Billion | ▼ -78.0% |
| 2012 | 0.36x | ₩13.97 Billion | ₩38.83 Billion | — |